Proliferative Diabetic Retinopathy

In reponse to poor circulation in the retina from diabetic retinopathy, new blood vessels sometimes grow. This is called proliferative diabetic retinopathy.

Does proliferative retinopathy Always Affect Vision?

No it does not always affect vision. It is possible to have advanced, sight threatening, proliferative diabetic retinopathy with normal vision. Proliferative diabetic retinopathy is an advanced for of diabetic eye disease. "Proliferative" means that there is growth, or "proliferation," of abnormal blood vessels in the back of the eye. Sometimes, very severe growth of abnormal blood vessels can also affect the front part of the eye. Proliferative diabetic retinopathy is a marker that diabetes has been present and poorly controlled for a long time. One of the theories that explains why abnormal new blood vessel growth occurs in diabetic eyes is that, as the normal small blood vessels in the eye become diseased and stop working well, the remaining vasculature begins to sprout new abnormal blood vessels. Often there vision is normal when proliferative abnormal blood vessel growth starts, which is one of the reasons it is vital that all diabetics receive regular dilated eye exams.

Proliferative Diabetic Retinopathy Treatment

Treatment for proliferative diabetic retinopathy has evolved over the last several decades. One of the most important aspects of treatment remains optimizing the blood sugar and systemic health in diabetes, since there is no way to completely stop diabetic retinopathy from getting worse when blood sugar, blood pressure, and other vascular diseases are under poor control. The mainstay of eye treatment for proliferative diabetic retinopathy remains a retinal laser procedure, called panretinal photocoagulation (PRP). PRP is performed in the office with either anesthesia drops or an anesthetic injection. It is very well-tolerated by patients, and has been shown repeatedly to reduce the risk of severe vision loss from proliferative diabetic retinopathy. Often, several sessions of panretinal photocoagulation are necessary. It is very important to understand that PRP laser treatment is not a cure for proliferative diabetic retinopathy, as there is no known cure for diabetes or its affects in the body. PRP treatment is very safe, and often helps keep patients from more invasive and extensive surgical procedures. Like every medical procedure, there are potential risks and side-effects to PRP laser. The specific risks and benefits of this type of laser will be discussed with every patient on an individualized basis.

What about Vitrectomy Surgery?

When proliferative diabetic retinopathy is advanced, vitrectomy surgery becomes necessary. That's why screening examinations are important so patients can be treated with laser before the proliferative retinopathy becomes so severe that surgery is necessary. Surgery can substantially reduce the risk of vision loss from severe proliferative diabetic retinopathy, but it does carry a risk from 10 percent to 20 percent of severe vision loss.

Nonclearing vitreous hemorrhage
  Traction retinal detachment involving the macula
  Combined tractional-rhegmatogenous retinal detachment
  Progressive active fibrovascular proliferation
  Macular edema associated with posterior hyaloidal traction
  Dense premacular hemorrhage
  Dense vitreous hemorrhage in the presence of anterior segment neovascularization

What about Anti-VEGF Therapy?

In addition to PRP laser, injectable therapy with anti-vascular endothelial growth factor (VEGF) medications has more recently played a role in the treatment of proliferative diabetic retinopathy. This is, at the moment, not an FDA approved treatment of proliferative retinopathy and is used sometimes to augment the affect of laser, not to replace laser. Since the mid-to-late 2000's, injections into the eye of small molecule antibody drugs have been shown to effectively treat the growth of abnormal new blood vessels. There are a variety of injectable drugs available, and these drugs are sometimes used on their own and are often combined with PRP laser treatment to cause the abnormal new blood vessels to stop growing. The injections are often used before there is extensive growth of abnormal new blood vessels. Injection therapy is administered in the office with either anesthetic drops or an anesthesia injection. It is also well-tolerated by patients, and the eye is often completely comfortable by the morning after the injection procedure. Injectable treatments often have to be repeated, as, with any medicine, the treatment effect of the injections is transient. Injection therapy similar to laser treatment, is very safe. Like any medical procedure, there are potential risks and side-effects to the injections, and these specific issues will be discussed with each patient on an individualized basis. Recently there has been evidence that after intensive injection therapy there is significant reversal of some signs of diabetic retinopathy, and injection therapy can sometimes be given less frequently over time. As injection therapy for proliferative diabetic retinopathy is relatively new, its role in the treatment of abnormal new blood vessels is going to evolve and change over time. Our practice is active in developing the best practices in injection therapy, and we have presented research involving injection dosing in diabetes at the American Society of Retina Specialists meeting in 2013 and 2014.

Proliferative Diabetic Retinopathy NEWS

Below are current articles from a Google News Feed on Proliferative Diabetic Retinopathy

Diabetes Eye Exam Frequency in US Is 'Alarmingly Low'  Medscape

The frequency of eye exams among insured patients with type 1 and type 2 diabetes in the United States is "alarmingly low," new research indicates. Findings ...

Proliferative Diabetic Retinopathy Therapeutics Market Research Report 2019 to 2025  News Eminency

This Research Report Forecast 2019-2025 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis ...

Diabetic Retinopathy: 2-Year Screening Interval May Be Okay  Medscape

People with diabetes who have minimal or no retinopathy at initial screening are unlikely to progress to the point of requiring retinopathy treatment within 2 years ...

Diabetic Retinopathy Market Growth Opportunity and Industry Revenue Analysis by Major Players, 2014-2022 |  Medgadget

The Global Diabetic Retinopathy Market generated $966 million in 2015 and is projected to attain $2.5 billion by 2022, registering a CAGR of 14.4% during.

Regeneron presents positive data from PANORAMA trial  Healio

Patients in the PANORAMA trial who underwent early intervention with Eylea experienced improvements in diabetic retinopathy severity, and the majority ...

Proliferative Diabetic Retinopathy Therapeutics Market Analysis 2019 to 2025  News Eminency

The report provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report ...

Diabetics urged to look out for eye disease symptoms  The Times

About 1000 diabetics every year are being diagnosed with advanced eye disease that could put their sight at risk, new figures reveal, writes Valerie Flynn.

Google’s Effort to Prevent Blindness Shows AI Challenges  The Wall Street Journal

Google has developed artificial intelligence that can detect a condition that causes blindness in diabetic patients, though tests in India demonstrate the ...

Ophthalmology Conference: The 5th Annual Congress on Controversies Ophthalmology: Asia-Australia (COPHy AA) - Shanghai February 21-23, 2019  MD Linx

COPHy AA again will be devoted to evidence-based debates and discussions amongst session moderators, speakers and the audience, all of whom will ...

More Reasons To Use Statins For Diabetes Treatment  Diabetes In Control

Treatment with statins for diabetes associated with lower risks of major adverse cardiovascular events, retinopathy, neuropathy, and foot ulcers.

Proliferative Diabetic Retinopathy Market 2019: Global Key Players Intas Pharmaceuticals, Santen Pharmaceutical, Valeant Pharmaceuticals International  Buffalo Morning Star

Global Proliferative Diabetic Retinopathy Market Research Report 2018 from MarketAndResearch.biz offers a comprehensive study including company's ...

Top News in Ophthalmology February 04 2019 (1 of 1)  MD Linx

Strong glycemic control may optimize vision outcomes in patients with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor ...

Proliferative Diabetic Retinopathy Market Growth Analysis by Key Manufacturer Merck KGaA, Cipla, Genentech  Fashion Herald

HTF MI recently introduced Global Proliferative Diabetic Retinopathy Market study with focused approach on market size & volumes by Application, Industry ...

Diabetic Retinopathy Market Future Scope, Demands and Projected Industry Growths  News.MarketSizeForecasters.com

MarketStudyReport.com present the report on global Diabetic Retinopathy Market evaluates the growth trends of the industry through historical study and ...

Global Diabetic Retinopathy Market Industry Scenario Till 2027  Tech News Store

Global Diabetic Retinopathy Market 2018 report provides a global analysis of Diabetic Retinopathy market data from 2018 to 2027. The report reveals the ...

Global Proliferative Diabetic Retinopathy Market Research Report 2019 to 2025: By Product, Application, Manufacturer, Sales and Segmentation  Cryptocurrency News

MarketResearchNest.com presents “Global Proliferative Diabetic Retinopathy Market Research Report 2019” new Research to its studies database.

Global Diabetic Retinopathy Market Expected to Reach USD 9.3 Billion By 2024: Zion Market Research  Industry News Press

The “Diabetic Retinopathy Market – by Type (Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy) and by Management (Vitrectomy, ...

Comparing of Nemaura Medical Inc. (NMRD) and IRIDEX Corporation (NASDAQ:IRIX)  The Hi New Ulm

Since Nemaura Medical Inc. (NASDAQ:NMRD) and IRIDEX Corporation (NASDAQ:IRIX) are part of the Medical Appliances & Equipment industry, they are ...

Global Proliferative Diabetic Retinopathy Market Study 2019 by Manufacturers Intas Pharmaceuticals, Santen Pharmaceutical, Allergan Plc  Crypto News

2019-2026 Proliferative Diabetic Retinopathy Market Report. Global Proliferative Diabetic Retinopathy Market report covers the present and future scenario and ...

Anti-VEGF vs PRP for Proliferative Diabetic Retinopathy  Medscape

Diabetic retinopathy (DR) is a leading cause of vision loss and blindness among the adult population. Clinical manifestations of DR include microaneurysms, ...

Impact of age of onset on incidence of retinopathy in T1D | Diabetes Care  MD Linx

In a population-based observational study, researchers assessed sex, age at diabetes onset, puberty, and HbA1c, with subjects followed from diabetes ...

Sweeteners have bitter effect  Deccan Chronicle

Hyderabad: Drinking diet soda may increase the risk for a severe type of diabetic eye disease that can lead to blindness, a new study has revealed. The study ...

Long-term results support PRP or ranibizumab for proliferative diabetic retinopathy  Healio

VANCOUVER, British Columbia — The 5-year outcomes from the DRCR.net Protocol S study support the use of either ranibizumab or panretinal ...

Diabetic Retinopathy Market Size, Analysis and Forecast up to 2025  Honest Version

Diabetes is a lifelong chronic disease caused by excessive levels of glucose in the blood mainly due to lack or insufficiency of insulin hormone to metabolize the ...

Diet Soda Linked to Increased Risk for Diabetic Retinopathy  Medscape

Diet soda, but not regular soda, was linked to increased risk for proliferative diabetic retinopathy, a study found; further studies are needed to confirm these ...

Diet soda consumption associated with increased risk of diabetic retinopathy  Healio

Researchers found that patients with diabetes who consumed more than four cans per week of a diet soft drink had a more-than-twofold risk of having ...

FDA to Review Eylea for the Treatment of Non-Proliferative Diabetic Retinopathy - MPR  Monthly Prescribing Reference

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) of Eylea (aflibercept; Regeneron) for the ...

Skipping Treatment for Diabetic Retinopathy Carries Risks  Medscape

Drs Jason Hsu and Anthony Obeid on how the 25% of patients lost to follow-up are vulnerable to vision loss and other adverse outcomes.

Regeneron's Eylea Injection Meets Main Goals in Non-Proliferative Diabetic Retinopathy Study  R & D Magazine

Regeneron Pharmaceuticalsannounced that the Phase 3 Panorama trial evaluating Eylea (aflibercept) Injection in patients with moderately severe and severe ...

Diabetic Retinopathy Treatment Industry 2019 Research Report Forecast 2025  Big Times News

Global Diabetic Retinopathy Treatment Market research report is delivering key insights and providing a competitive advantage to clients through a detailed ...

ICO Publishes New Guidelines for Diabetic Retinopathy  MD Magazine

Importantly, they are not directed toward ophthalmologists, but at general physicians and public healthcare professionals.

Diet Soda Associated with Increased Risk for Diabetic Retinopathy, Study  dLife.com

New findings show that drinking diet soda may increase the risk for proliferative diabetic retinopathy (PDR), a severe type of diabetic eye disease, according to ...

Statins May Prevent Diabetic Retinopathy in People with Diabetes  EndocrineWeb

Individuals with diabetes who were taking a statin for high blood cholesterol have the added benefit of reducing their risk of developing diabetic retinopathy, and ...

Diet Soda Linked to Risk for Diabetic Blindness  WebMD

Jan. 8, 2019 -- Drinking diet soda may raise the risk for a severe type of diabetic eye disease that can lead to blindness, a new study says. The study, published ...

Risk factors for neovascular glaucoma after vitrectomy in eyes with pr | OPTH  Dove Medical Press

Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy Masashi Sakamoto, Ryuya Hashimoto, Izumi Yoshida, ...

Benefits with Early Treatment of Diabetic Retinopathy  MedPage Today

VANCOUVER -- Almost 60% of patients with nonproliferative diabetic retinopathy (NPDR) had at least a two-step improvement in retinopathy score when treated ...

EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial  BioSpace

TARRYTOWN, N.Y., Oct. 25, 2018 /PRNewswire/ --. First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening ...

Aflibercept Reverses Nonproliferative Diabetic Retinopathy Progression  MD Magazine

Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.

Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN delivered impressive results in the fourth quarter of 2018 wherein both earnings and sales beat estimates..

Two Treatments, Similar Outcomes in Diabetic Retinopathy  MedPage Today

Two different approaches to treating proliferative diabetic retinopathy (PDR) led to similar improvement in visual acuity at 5 years, results of a randomized trial ...

Statin Therapy Reduces Risk for Diabetic Retinopathy in Type 2 Diabetes  The Cardiology Advisor

HealthDay News - For Taiwanese patients with type 2 diabetes and dyslipidemia, statin therapy is associated with a reduced risk for diabetic retinopathy, ...

IRadimed Corporation (IRMD) and IRIDEX Corporation (NASDAQ:IRIX) Contrasting side by side  The Hi New Ulm

As Medical Appliances & Equipment companies, IRadimed Corporation (NASDAQ:IRMD) and IRIDEX Corporation (NASDAQ:IRIX) are our subject to contrast.

Propranolol for Proliferative Diabetic Retinopathy  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To determine the effect of propranolol on retinal neovascularization due to ...

Opiant Pharmaceuticals Inc. (OPNT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) Comparison side by side  The Hi New Ulm

Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) have been rivals in the Biotechnology for quite some time.

Diabetic retinopathy position statement promotes prevention, early detection, control  Healio

A new position statement by the American Diabetes Association recommends intensive glycemic control and regular screening for prevention and early ...

Anti-VEGF/PRP Regresses Diabetic Retinopathy  Medscape

Taking a closer look at PROTEUS, an intriguing study in patients with high-risk proliferative diabetic retinopathy.

Centre Asset Management Decreased Holding in Regeneron Pharmaceuticals (REGN) as Market Valuation Declined; As Compass Minerals Int (CMP) Stock Declined, Shareholder Beacon Financial Group Trimmed Stake  The Hi New Ulm

Centre Asset Management Llc decreased its stake in Regeneron Pharmaceuticals (REGN) by 3.76% based on its latest 2018Q3 regulatory filing with the SEC.

Diabetic Retinopathy Market Business Growth Statistics and Key Players Insights: Novartis, Bayer Healthcare, Regeneron Pharmaceuticals, ThromboGenics  openPR

QY Research Groups has announced the addition of "Global Diabetic Retinopathy Market Size, Status and Forecast 2025" Market Research report to their ...

Contrasting of Proteostasis Therapeutics Inc. (PTI) and OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The Hi New Ulm

We are contrasting Proteostasis Therapeutics Inc. (NASDAQ:PTI) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) on their analyst recommendations, profitability ...

Brainstorm Cell Therapeutics Inc. (BCLI)'s Financial Results Comparing With OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The Hi New Ulm

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) have been rivals in the Biotechnology for quite some time.

Diabetic Retinopathy Treatment Market 2019-2025 by Research Methodology, Value Chain Analysis and Distributors – Daily Updates  Daily Updates

Diabetic Retinopathy Treatment Market report provides complete evaluation for those who are looking for Business expand in various regions, manufacturers, ...

Statins Cut Retinopathy Risk in Type 2 Diabetes  MedPage Today

Treatment with statins was associated with a significantly decreased risk of diabetic retinopathy in patients with type 2 diabetes and high cholesterol in a large ...

Diabetic Retinopathy: Reality and Risk of Loss to Follow-up  Medscape

Clinical studies on the treatments for diabetic retinopathy have focused on efficacy and safety, but the loss of patients to follow-up is a challenge that may be ...

Evidence mounts to support anti-VEGF to treat, prevent proliferative diabetic retinopathy  Healio

WAILEA, Hawaii — The current algorithm for the treatment of proliferative diabetic retinopathy is effective but is an inherently destructive treatment, according to ...

Ascentage Pharma And Unity Biotechnology Inc. (NASDAQ:UBX) Execute A New Compound License Agreement  FDA Headlines

Jan 24, 2019 | Business. Ascentage Pharma And Unity Biotechnology Inc. (NASDAQ:UBX) Execute A New Compound. Ascentage Pharma is it again with a new ...

Subthreshold microsecond laser for proliferative diabetic retinopathy: | OPTH  Dove Medical Press

Subthreshold microsecond laser for proliferative diabetic retinopathy: a randomized pilot study Mahima Jhingan,1 Abhilash Goud,1 Hari Kumar Peguda,1 Mitali ...

Reviewing BiondVax Pharmaceuticals Ltd. (BVXV)'s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)'s results  The Hi New Ulm

This is a contrast between BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) based on their institutional ...

Jason Hsu, MD: Tackling Treatment Adherence in Patients with Diabetic Retinopathy  MD Magazine

Anti-VEGF and pan-retinal photocoagulation can be effective, but neither are "one-and-done" therapies. Physicians must be proactive about how they handle ...

Considering Three Major Developments in the Diabetes Retinopathy Industry  MD Magazine

The DR market is expected to accrue a sum of $2490 million by 2022, growing at a compound annual growth rate of 14.4% from 2014-2022.

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy  PR Newswire

TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

New study shows diabetic retinopathy regression in high risk patients treated with Lucentis  The Pharma Letter

A new study published in Ophthalmology Retina evaluated diabetic retinopathy (DR) outcomes with Lucentis (ranibizumab) treatment in patients with DR and ...

Diabetic Retinopathy Market is Expected to Reach US$ XX Bn by 2025, Due to Increasing Incedence of Blindness Caused by Diabetes  openPR

“The Global Diabetic Retinopathy Market is anticipated to reach about US$ XX Bn by 2025, and anticipated to expand at a CAGR over seven years of forecast ...

Statin therapy reduces risk for diabetic retinopathy in T2DM  Medical Xpress

(HealthDay)—For Taiwanese patients with type 2 diabetes and dyslipidemia, statin therapy is associated with a reduced risk for diabetic retinopathy, according ...

Iridex Corporation (NASDAQ:IRIX) Stock Is Shorted More | Thorold News  Thorold News

Investors sentiment increased to 1.78 in 2018 Q3. Its up 0.98, from 0.8 in 2018Q2. It increased, as 2 investors sold IRIDEX Corporation shares while 7 reduced.

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial  PR Newswire

TARRYTOWN, N.Y., March 19, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 PANORAMA trial ...

Diabetic Retinopathy May Be Independent Risk Factor for Parkinson Disease  Endocrinology Advisor

Results support that there is a relationship between diabetic retinopathy and Parkinson disease.

New reports suggest strong growth for global Diabetic Retinopathy market  Business Facts Today

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which ...

Diabetic Retinopathy - A Drug Pipeline Analysis Report by Technavio  Business Wire

Technavio has published a new report on the drug pipeline for the treatment of diabetic retinopathy, including a detailed study of the molecules.

Proliferative Diabetic Retinopathy: New Data  Medscape

Diabetic retinopathy (DR) is a leading cause of vision loss around the world, and remains the most common cause of blindness among working-age people in ...

Time in Range According to CGM Associated With Diabetic Retinopathy  Endocrinology Advisor

Investigators assessed the time in range according to a continuous glucose monitor and the risk for diabetic retinopathy.

New Acucela Data on the Effect of Emixustat Hydrochloride on Retinal Thickness in Diabetic Retinopathy  Business Wire

SEATTLE--(BUSINESS WIRE)--Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical ...

Consumption of diet soda linked to diabetic retinopathy  Specialty Medical Dialogues

It is a surprise Finding! Diet soda, not sugary soft drinks linked to diabetic retinopathy. Consumption of more than 4 cans of diet soda (1.5 L) per week is ...

Eylea positive in diabetic retinopathy, but analysts skeptical  BioPharma Dive

Regeneron Pharmaceuticals Inc. revealed positive Phase 3 results for Eylea in moderately severe to severe non-proliferative diabetic retinopathy patients ...

AAP, others issue updated recommendations on retinopathy of prematurity  AAP News

Retinopathy of prematurity (ROP) is a developmental disorder of the eye occurring in small, very premature neonates. In some cases, if untreated, it results in ...

Proliferative Diabetic Retinopathy Independently Associated With CVD in T1D  Endocrinology Advisor

Study found that the absence of proliferative diabetic retinopathy in those with stage 3b chronic kidney disease is associated with a lower prevalence of ...

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

Outcomes Worse with Anti-VEGF than PRP in Patients Lost to Follow-Up  MD Magazine

Eyes that received only anti-VEGF experienced significantly worse visual acuity from initial visit to final visit.

Sentiment Change Report: Iridex Corp (NASDAQ:IRIX) | Thorold News  Thorold News

Iridex Corp (NASDAQ:IRIX) institutional sentiment increased to 1.78 in 2018 Q3. Its up 0.98, from 0.8 in 2018Q2. The ratio is better, as 16 active investment ...

Intravitreal Bevacizumab Revolutionizing Treatment of Diabetic Retinopathy  The Center for Biosimilars

Intravitreal injection of bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, ...

FDA Approves Unique Device for Diabetic Retinopathy Screening - MPR  Monthly Prescribing Reference

The Food and Drug Administration (FDA) has granted marketing clearance to IDx-DR (IDx LLC), the first artificial intelligence (AI)-based medical device to detect ...

Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy  Business Wire

Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases a.

Sesen Bio Inc. (SESN) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) Comparing side by side  D Minute

Sesen Bio Inc. (NASDAQ:SESN) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) compete against each other in the Biotechnology sector. We will compare ...

Zacks: Analysts Anticipate IRIDEX Co. (IRIX) to Announce -$0.25 EPS  Fairfield Current

Analysts expect IRIDEX Co. (NASDAQ:IRIX) to post earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research.

Algorithm Detects Diabetic Retinopathy in Retinal Images with 97% Accuracy  MD Magazine

The deep learning algorithm was tested on 71000 images, and offers the potential to significantly increase the speed at which DR can be identified.

Contrasting of OHR Pharmaceutical Inc. (OHRP) and Therapix Biosciences Ltd. (NASDAQ:TRPX)  The Moveefy

This is therefore a contrasting of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in OHR.

Ranibizumab Beats Laser for Diabetic Retinopathy  Medscape

BARCELONA, Spain — Ranibizumab treats proliferative diabetic retinopathy more effectively than laser photocoagulation, researchers reported here at the 17th ...

Reviewing OHR Pharmaceutical Inc. (OHRP)'s and Cerus Corporation (NASDAQ:CERS)'s results  The Yomi Blog

As Biotechnology businesses, OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Cerus Corporation (NASDAQ:CERS), are affected by compare. This especially ...

OHR Pharmaceutical Inc. (OHRP) and Clearside Biomedical Inc. (NASDAQ:CLSD) Comparison side by side  EN Digest

Both OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Clearside Biomedical Inc. (NASDAQ:CLSD) are Biotechnology companies, competing one another.

Acadian Asset Management Holding in Regeneron Pharmaceuticals (REGN) Has Lifted by $7.94 Million as Stock Price Declined; Qualcomm (QCOM) Valuation Declined While Arcadia Investment Management Has Cut Its Position  The Moveefy

Acadian Asset Management Llc increased its stake in Regeneron Pharmaceuticals (REGN) by 1322.27% based on its latest 2018Q3 regulatory filing with the ...

Proliferative Diabetic Retinopathy: Outcomes With Ranibizumab vs Panretinal Photocoagulation  Clinical Pain Advisor

Cumulative probability of proliferative diabetic retinopathy worsening was 42% in the panretinal photocoagulation group vs 34% in the ranibizumab group.

Contrasting of Rocket Pharmaceuticals Inc. (RCKT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The Moveefy

Both Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are each other's competitor in the Biotechnology industry.

The Many Ways Diabetes Affects Your Eyes  Star2.com

Diabetes can affect the eyes in many ways. Diabetic retinopathy affects blood vessels in the light-sensitive tissue called the retina that lines the back of the eye.

Reviewing Alnylam Pharmaceuticals Inc. (ALNY)'s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)'s results  EN Digest

Since Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are part of the Biotechnology industry, they are ...

Comparing of OHR Pharmaceutical Inc. (OHRP) and Cellectar Biosciences Inc. (:)  The Moveefy

OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Cellectar Biosciences Inc. (:), both competing one another are Biotechnology companies. We will contrast their ...

Fighting diabetic blindness: Researchers develop new target to study potential treatments  Medical Xpress

Diabetic retinopathy is a retinal microvascular disease that often causes blindness in adults who have had diabetes mellitus for 10 years or more. Estimates are ...

Reviewing OHR Pharmaceutical Inc. (OHRP)'s and CytomX Therapeutics Inc. (NASDAQ:CTMX)'s results  EN Digest

As Biotechnology companies, OHR Pharmaceutical Inc. (NASDAQ:OHRP) and CytomX Therapeutics Inc. (NASDAQ:CTMX) are our subject to contrast. And more ...

Diabetic Retinopathy Risk Increased With Diet Soda Consumption  Endocrinology Advisor

HealthDay News — Diet soda consumption may up the odds of diabetic retinopathy (DR), according to a study published online in Clinical & Experimental ...

Diabetes No Barrier to Cataract Surgery | Medpage Today  MedPage Today

CHICAGO -- Diabetic patients without retinopathy achieved 20/20 vision after cataract surgery as often as nondiabetic patients did, a retrospective analysis of a ...

Iridex Corp (NASDAQ:IRIX): Positive Stock Sentiment | Thorold News  Thorold News

Iridex Corp (NASDAQ:IRIX) institutional sentiment increased to 1.78 in Q3 2018. Its up 0.98, from 0.8 in 2018Q2. The ratio is more positive, as 16 institutional ...

» Load more